Retatrutide Phase 3 Data: The Most Powerful GLP-1 Ever
Retatrutide is the first triple G agonist targeting GLP-1, GIP, and Glucagon receptors simultaneously. Wayne Stevenson and Victoria break down the Phase 3 TRIUMPH trial data, the 25% weight loss numbers, muscle loss risks, and the Builder’s 4-pillar protection protocol.
